The FDA approves a new 72 mcg dose of LINZESS (linaclotide) for the treatment of patients with chronic idiopathic constipation (CIC). The original approved dosage for CIC was 145 mcg. For IBS-C, it is 290 mcg.
Now read: Buy Allergan If It Dips »
Subscribe for full text news in your inbox